Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology

Sector: Healthcare

Phone: 609-322-1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

cartman1929 Dec. 4 at 11:25 PM

$GRCE Consolidation is over. Hold, enjoy or buy more.

0 · Reply

CharlieeMungerTWITS Dec. 4 at 7:55 PM

$GRCE

0 · Reply

Drashkawisha Dec. 4 at 6:17 PM

$GRCE

0 · Reply

RunningRobert1 Dec. 3 at 3:06 PM

$GRCE https://www.youtube.com/watch?v=qZdhpZi_mes Please join me for a Live Stream today were we will be looking at the best microcap stocks for 2026. If you see this it is because your stock is in the top

1 · Reply

Drashkawisha Dec. 2 at 12:40 PM

$GRCE The fear of the $3.40 warrant overhang is misunderstood. Institutions aren't selling there because they lack conviction on the April PDUFA. They are selling to de-risk and secure a "Free Ride" on house money. Let them feed the liquidity. Cash runway Clinical differentiation PDUFA April 2026 Once we chew through the $3.40 supply, the real gap up begins.

0 · Reply

Drashkawisha Dec. 1 at 7:19 AM

$GRCE Bullish on the GTx-104 data and the unmet need in the ICU. The clinical case is strong. However, looking at the Q3 filings - cash runway seems tight (<12 months) with the "going concern" note. For those tracking closely: Do you expect them to bridge the gap to the April PDUFA with the ATM facility, or are you modeling in a direct offering/dilution event before the approval? Trying to time my entry properly

1 · Reply

JujuInvestor2013 Nov. 30 at 1:46 PM

$GRCE waiting since 6 months - 62k in because i truly think that it may x3 / x5 untill april 2026, very small float, lot of green signals, just being patient before take off 🚀🚀🚀🙏

1 · Reply

CharlieeMungerTWITS Nov. 27 at 11:23 AM

$GRCE wowza $6 by March

0 · Reply

jjangles123 Nov. 26 at 8:16 PM

$GRCE I’m in with a small position. What do we see from now until April?

1 · Reply

CharlieeMungerTWITS Nov. 24 at 12:22 AM

$GRCE I’m ready for you!

0 · Reply

Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Nov 13, 2025, 8:00 AM EST - 21 days ago

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

Nov 11, 2025, 8:30 AM EST - 23 days ago

Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Sep 22, 2025, 8:00 AM EDT - 2 months ago

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 18, 2025, 8:30 AM EDT - 2 months ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 4, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 12, 2025, 8:00 AM EDT - 4 months ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 13, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 8 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 9 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 10 months ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 10 months ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 10 months ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 10 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 10 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 11 months ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 2 years ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 2 years ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 2 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 2 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 8, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Feb 28, 2023, 1:00 PM EST - 3 years ago

Acasti Pharma Recognizes Rare Disease Day

cartman1929 Dec. 4 at 11:25 PM

$GRCE Consolidation is over. Hold, enjoy or buy more.

0 · Reply

CharlieeMungerTWITS Dec. 4 at 7:55 PM

$GRCE

0 · Reply

Drashkawisha Dec. 4 at 6:17 PM

$GRCE

0 · Reply

RunningRobert1 Dec. 3 at 3:06 PM

1 · Reply

Drashkawisha Dec. 2 at 12:40 PM

0 · Reply

Drashkawisha Dec. 1 at 7:19 AM

1 · Reply

JujuInvestor2013 Nov. 30 at 1:46 PM

$GRCE waiting since 6 months - 62k in because i truly think that it may x3 / x5 untill april 2026, very small float, lot of green signals, just being patient before take off 🚀🚀🚀🙏

1 · Reply

CharlieeMungerTWITS Nov. 27 at 11:23 AM

$GRCE wowza $6 by March

0 · Reply

jjangles123 Nov. 26 at 8:16 PM

$GRCE I’m in with a small position. What do we see from now until April?

1 · Reply

CharlieeMungerTWITS Nov. 24 at 12:22 AM

$GRCE I’m ready for you!

0 · Reply

CharlieeMungerTWITS Nov. 21 at 2:57 PM

$GRCE

0 · Reply

jjangles123 Nov. 18 at 6:49 PM

$GRCE seems pretty stable, pdufa end of April? Cash runway until Q3 ‘26? Can anyone enlighten me on getting in now?

1 · Reply

RunningRobert1 Nov. 17 at 2:20 PM

$GRCE Grace Therapeutics GRCE 3Q 2025 Summary 17Nov2025 https://youtu.be/V_d2m8gsY1k PDUFA is less then 2 quarters (23Apr2026) overall I would expect some run up going in next year, and then we will safety withdraw the original investment, and then free-rolling into the PDUFA

1 · Reply

Mikshagav Nov. 14 at 12:39 PM

$GRCE added more please don’t disappoint me🥹

0 · Reply

BB_88_ Nov. 14 at 12:54 AM

$GRCE Q1 they will run it

0 · Reply

JujuInvestor2013 Nov. 5 at 8:22 AM

$GRCE very interesting yesterday … bid and ask 😉📈🚀

0 · Reply

shade00tree Nov. 2 at 4:36 PM

$GRCE

1 · Reply

bdetweiler Oct. 31 at 7:16 PM

$GRCE This is the most boring stock.

1 · Reply

RunningRobert1 Oct. 29 at 7:27 PM

$GRCE Grace Therapeutics GRCE Summary 27Oct2025 https://youtu.be/F_ZoYvrrV-c A little late in posting, but nothing has changed since the summary went out. Overall with a under 50M market cap and a small net loss, approval and sales could easily turn this into a profitable company, thought we know from past exp. that hospital sales start slow. Overall bullish and could get a double before the PDUFA date

0 · Reply

shade00tree Oct. 21 at 12:15 PM

$GRCE free float of the company is about 12.3M. Be wary of pumpers.

0 · Reply

JujuInvestor2013 Oct. 17 at 6:58 PM

$GRCE Short position increased from 0.8 to 3.70% (352 000 shares) …one day it will pop because we have a very low float (9M)

0 · Reply

Doozio Oct. 15 at 10:05 PM

🐑 gonna need $GRCE out of the tightness da 🧠 shall spread 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	48.59M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	77,400
Avg Vol	64,414
Day's Range	N/A - N/A
Shares Out	15.47M
Stochastic %K	100%
Beta	0.59
Analysts	Strong Sell
Price Target	$11.83